Compass Pathways' Leads the Way as the First Psychedelics Company To IPO on the Nasdaq

NEW YORK, Sept. 24, 2020 /PRNewswire/ -- Last year may have been all about cannabis, but it's clear that 2020 and beyond belongs to the psychedelic medicine market. Ever since Johnson & Johnson's (NYSE:JNJ) ketamine-derived medicine, Spravato, received the first nod of approval from the...